about
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized mya...
Read More
831.71
4.69
(0.57%)
79,112
XNAS Volume
XNAS 23 Jan, 2026 10:45 AM (EST)
Medium Financial Strength
Mid Valuation
Technically Moderately Bullish
Turnaround Potential
These stocks have average financials and valuation, but strong momentum indicating buying interest
View Similar
Embed DVM
Argen X SE (ADR) Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..